Study identifier:D7980C00006
ClinicalTrials.gov identifier:NCT05685472
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Japanese Subjects with Advanced Solid Tumors
Advanced Solid Tumors
Phase 1
No
-
All
6
Interventional
18 Years - 120 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 May 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: MEDI5752 monotherapy | - |